Evolution Of Clinical Trials In The Asia Pacific Region

Over the last five years, the global clinical trial landscape has changed significantly. During the analysis period between 2017-2021, over 70,000 new clinical trials were registered in the APAC region, the US, and the EU⁵. The APAC region was the largest contributor, with more than 50% of the trials followed by the US (29%) and the EU5 (17%). During this period, the highest growth was witnessed in the APAC region (CAGR of 14%), while the US grew marginally, and negative growth was observed in the EU⁵. The APAC region has become the preferred destination for conducting clinical trials due to its large patient population, ease of regulatory compliance, low cost of conducting studies, high-quality standards and the presence of top clinical institutions acting as sites. Notably, China’s regulatory reforms have accelerated drug approval by reducing the overall review and process.